A comparison of the long-term effects of lanthanum carbonate and calcium carbonate on the course of chronic renal failure in rats with adriamycin-induced nephropathy

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Takashima, Tsuyoshi ^a   Sanai, Toru ^b   Miyazono, Motoaki ^a   Fukuda, Makoto ^a   Kishi, Tomoya ^a   Nonaka, Yasunori ^c   Yoshizaki, Mai ^a   Sato, Sae ^a   Ikeda, Yuji ^a  

^a SAGA UNIVERSITY   (Japan)

^b Fukumitsu Hospital   (Japan)

^c Ureshino Medical Center   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CALCIUM CARBONATE; CREATININE; DOXORUBICIN; LANTHANUM CARBONATE; PHOSPHATE; BETA GLUCURONIDASE; KLOTHO PROTEIN; LANTHANUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DRUG BINDING; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG POTENCY; KIDNEY DISEASE; MALE; MOUSE; NONHUMAN; PHOSPHATE BLOOD LEVEL; PHOSPHATE URINE LEVEL; UREA NITROGEN BLOOD LEVEL; WEIGHT GAIN; ANIMAL; BLOOD PRESSURE; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TEST; METABOLISM; PATHOPHYSIOLOGY; RAT; TIME;

ANIMALS; BLOOD PRESSURE; CALCIUM CARBONATE; DISEASE MODELS, ANIMAL; DOXORUBICIN; GLUCURONIDASE; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; LANTHANUM; MALE; RATS; TIME FACTORS;

EID: 84901365414     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0097859     Document Type: Article

References (33)

1. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, et al. (2004) Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15: 2208-2218. (Pubitemid 39031360)
2. Danese MD, Belozeroff V, Smirnakis K, Rothman KJ (2008) Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin J Am Soc Nephrol 3: 1423-1429.
3. Ibels LS, Alfrey AC, Haut L, Huffer WE (1978) Preservation of function in experimental renal disease by dietary restriction of phosphate. N Engl J Med 298: 122-126.
4. Karlinsky ML, Haut L, Buddington B, Schrier NA, Alfrey AC (1980) Preservation of renal function in experimental glomerulonephritis. Kidney Int 17: 293-302. (Pubitemid 10101588)
5. Laouari D, Kleinknecht C, Cournot-Witmer G, Habib R, Mounier F, et al. (1982) Beneficial effect of low phosphorus diet in uraemic rats: a reappraisal. Clin Sci (Lond) 63: 539-548. (Pubitemid 13213945)
6. Lumlertgul D, Burke TJ, Gillum DM, Alfrey AC, Harris DC, et al. (1986) Phosphate depletion arrests progression of chronic renal failure independent of protein intake. Kidney Int 29: 658-666. (Pubitemid 16164573)
7. Sanai T, Okuda S, Motomura K, Onoyama K, Fujishima M (1989) Effect of phosphate binders on the course of chronic renal failure in rats with focal glomerular sclerosis. Nephron 51: 530-535. (Pubitemid 19076378)
8. Okuda S, Oh Y, Tsuruda H, Onoyama K, Fujimi S, et al. (1986) Adriamycin-induced nephropathy as a model of chronic progressive glomerular disease. Kidney Int 29: 502-510. (Pubitemid 16129061)
9. Bertani T, Cutillo F, Zoja C, Broggini M, Remuzzi G (1986) Tubulo-interstitial lesions mediate renal damage in adriamycin glomerulopathy. Kidney Int 30: 488-496. (Pubitemid 16000793)
10. Persy VP, Behets GJ, Bervoets AR, De Broe ME, D'Haese PC (2006) Lanthanum: a safe phosphate binder. Semin Dial 19: 195-199. (Pubitemid 43742655)
11. Behets GJ, Dams G, Vercauteren SR, Damment SJ, Bouillon R, et al. (2004) Does the phosphate binder lanthanum carbonate affect bone in rats with chronic renal failure? J Am Soc Nephrol 15: 2219-2228. (Pubitemid 39031361)
12. Hutchison AJ, Maes B, Vanwalleghem J, Asmus G, Mohamed E, et al. (2005) Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin Pract 100: c8-19.
13. Daugirdas JT, Finn WF, Emmett M, Chertow GM (2011) The phosphate binder equivalent dose. Semin Dial 24: 41-49.
14. Hutchison AJ (2004) Improving phosphate-binder therapy as a way forward. Nephrol Dial Transplant 19 Suppl 1: i19-24.
15. Russo D, Miranda I, Ruocco C, Battaglia Y, Buonanno E, et al. (2007) The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int 72: 1255-1261. (Pubitemid 350059663)
16. Burke SK, Slatopolsky EA, Goldberg DI (1997) RenaGel, a novel calcium- and aluminium-free phosphate binder, inhibits phosphate absorption in normal volunteers. Nephrol Dial Transplant 12: 1640-1644. (Pubitemid 27346290)
17. Sprague SM, Abboud H, Qiu P, Dauphin M, Zhang P, et al. (2009) Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial. Clin J Am Soc Nephrol 4: 178-185.
18. Gonzalez-Parra E, Gonzalez-Casaus ML, Galan A, Martinez-Calero A, Navas V, et al. (2011) Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients. Nephrol Dial Transplant 26: 2567-2571.
19. Pennick M, Poole L, Dennis K, Smyth M (2012) Lanthanum carbonate reduces urine phosphorus excretion: evidence of high-capacity phosphate binding. Ren Fail 34: 263-270.
20. D'Haese PC, Spasovski GB, Sikole A, Hutchison A, Freemont TJ, et al. (2003) A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl: S73-78. (Pubitemid 36605868)
21. Klahr S, Buerkert J, Purkerson ML (1983) Role of dietary factors in the progression of chronic renal disease. Kidney Int 24: 579-587. (Pubitemid 14208752)
22. Walser M, Mitch WE, Collier VU (1979) The effect of nutritional therapy on the course of chronic renal failure. Clin Nephrol 11: 66-70. (Pubitemid 9128636)
23. Gimenez LF, Solez K, Walker WG (1987) Relation between renal calcium content and renal impairment in 246 human renal biopsies. Kidney Int 31: 93-99. (Pubitemid 17006349)
24. Katz AI, Epstein FH (1968) Physiologic role of sodium-potassium-activated adenosine triphosphatase in the transport of cations across biologic membranes. N Engl J Med 278: 253-261.
25. Israel Y, Videla L, Fernandez-Videla V, Bernstein J (1975) Effects of chronic ethanol treatment and thyroxine administration on ethanol metabolism and liver oxidative capacity. J Pharmacol Exp Ther 192: 565-574.
26. Serros ER, Kirschenbaum MA (1981) Prostaglandin-dependent polyuria in hypercalcemia. Am J Physiol 241: F224-230.
27. Lins LE (1978) Reversible renal failure caused by hypercalcemia. A retrospective study. Acta Med Scand 203: 309-314.
28. Spasovski G (2008) New strategies in treatment of mineral and bone disorders and associated cardiovascular disease in patients with chronic kidney disease. Recent Pat Cardiovasc Drug Discov 3: 222-228.
29. Damment SJ (2011) Pharmacology of the phosphate binder, lanthanum carbonate. Ren Fail 33: 217-224.
30. Chiang SS, Chen JB, Yang WC (2005) Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease. Clin Nephrol 63: 461-470.
31. Hutchison AJ, Maes B, Vanwalleghem J, Asmus G, Mohamed E, et al. (2006) Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study. Nephron Clin Pract 102: c61-71. (Pubitemid 43087563)
32. Finn WF (2006) Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. Clin Nephrol 65: 191-202.
33. Hutchison AJ, Barnett ME, Krause R, Kwan JT, Siami GA (2008) Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment. Nephron Clin Pract 110: c15-23.